Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Overtreatment of Low-Risk Patients With Atrial Fibrillation—The Quality Coin Has 2 Sides—Reply

Overtreatment of Low-Risk Patients With Atrial Fibrillation—The Quality Coin Has 2 Sides—Reply Letters 5. Kahneman D, Knetsch JL, Thaler RH. Experimental tests of the endowment the opt-out group [38.5%]; P = .09). and the effects may be lim- effect and the Coase theorem. J Polit Econ. 1990;98(6):1325-1348. doi:10.1086 ited to interventions with tangible devices, so larger studies are /261737. needed to confirm findings in other populations and condi- tions. For low-risk interventions, opt-out approaches can im- prove the efficiency of recruitment, expand the intervention to COMMENT & RESPONSE those who are otherwise less likely to participate, and increase Overtreatment of Low-Risk Patients With generalizability of clinical trials to a broader population. Atrial Fibrillation—The Quality Coin Has 2 Sides To the Editor I read with interest the article by Hsu et al in the Shivan J. Mehta, MD, MBA, MSHP April issue of JAMA Cardiology. The article highlighted that less Andrea B. Troxel, ScD than 50% of patients with atrial fibrillation with CHADS scores Noora Marcus, MA 2 exceeding 3 received oral anticoagulation therapy with war- Christina Jameson, BS farin or a nonvitamin K antagonist anticoagulant, even in the Devon Taylor, BS American College of Cardiology National Cardiovascular Data David A. Asch, MD, MBA Registry Practice Innovation and Clinical Excellence Regis- Kevin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Overtreatment of Low-Risk Patients With Atrial Fibrillation—The Quality Coin Has 2 Sides—Reply

Loading next page...
 
/lp/american-medical-association/overtreatment-of-low-risk-patients-with-atrial-fibrillation-the-sADwZGa0xf
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2016.2273
pmid
27541439
Publisher site
See Article on Publisher Site

Abstract

Letters 5. Kahneman D, Knetsch JL, Thaler RH. Experimental tests of the endowment the opt-out group [38.5%]; P = .09). and the effects may be lim- effect and the Coase theorem. J Polit Econ. 1990;98(6):1325-1348. doi:10.1086 ited to interventions with tangible devices, so larger studies are /261737. needed to confirm findings in other populations and condi- tions. For low-risk interventions, opt-out approaches can im- prove the efficiency of recruitment, expand the intervention to COMMENT & RESPONSE those who are otherwise less likely to participate, and increase Overtreatment of Low-Risk Patients With generalizability of clinical trials to a broader population. Atrial Fibrillation—The Quality Coin Has 2 Sides To the Editor I read with interest the article by Hsu et al in the Shivan J. Mehta, MD, MBA, MSHP April issue of JAMA Cardiology. The article highlighted that less Andrea B. Troxel, ScD than 50% of patients with atrial fibrillation with CHADS scores Noora Marcus, MA 2 exceeding 3 received oral anticoagulation therapy with war- Christina Jameson, BS farin or a nonvitamin K antagonist anticoagulant, even in the Devon Taylor, BS American College of Cardiology National Cardiovascular Data David A. Asch, MD, MBA Registry Practice Innovation and Clinical Excellence Regis- Kevin

Journal

JAMA CardiologyAmerican Medical Association

Published: Oct 17, 2016

References